Get the Stockscreener App
2.33
0.43%
0.01
Nervgen Pharma Corp stock is traded at $2.33, with a volume of 920.52K.
It is up +0.43% in the last 24 hours and up +40.36% over the past month.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$2.32
Open:
$2.31
24h Volume:
920.52K
Relative Volume:
0.97
Market Cap:
$250.53M
Revenue:
-
Net Income/Loss:
$-31.64M
P/E Ratio:
-5.5135
EPS:
-0.4226
Net Cash Flow:
$-13.98M
1W Performance:
+2.19%
1M Performance:
+40.36%
6M Performance:
-45.43%
1Y Performance:
+0.00%
1-Day Range:
$2.275
$2.395
1-Week Range:
$2.1001
$2.395
52-Week Range:
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
2.33 | 189.24M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
Nervgen Pharma Corp Stock (NGEN) Latest News
What Makes NervGen Pharma (TSXV:NGEN) A Biotech Watchlist Name? - Kalkine Media
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, F - GuruFocus
NervGen Pharma (HAM:9UA) Cyclically Adjusted PS Ratio : (As of Aug. 16, 2026) - GuruFocus
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportAndrews Pitchfork - dars.gov.et
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Q2 FY26 net loss widens to C$29.2 million - Bitget
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NervGen Pharma (NGEN) Q3 2025 Earnings: Narrower-than-Expected Loss as Pipeline Development Continues - vinanet.vn
NervGen Pharma (NGEN) Edges Higher to $1.62, Holding Above Key Support LevelBackspread Trade - vinanet.vn
NGEN Q3 2025 Earnings: Narrower Net Loss Brings a 0.99 Percent Positive SurpriseEBITDA Estimate Trend - vinanet.vn
NervGen Pharma (NGEN) Holds Near Support as Price Pullback Tests Key LevelsMoney Flow - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NGEN Q3 2025 Earnings: Narrower Loss Surprises as Clinical Pipeline Progress ContinuesEarnings Weakness Phase - Vinanet
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NervGen Pharma (NGEN) Slips 1.45% as Stock Tests Key Support Near $1.61Descending Triangle - vinanet.vn
NGEN Q3 2025 Earnings: Slight EPS Beat Amid Ongoing Pipeline DevelopmentPre-Earnings Setup - vinanet.vn
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
H.C. Wainwright cuts NervGen stock price target to $15 on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Nigeria
NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key SupportRelative Volume - dars.gov.et
NGEN Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - Moomoo
NervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink Partners - MarketBeat
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Small EPS Beat as Pipeline Progress Underpins Market Confidence - dars.gov.et
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):